Abstract:Background Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a life-threatening disease with a high mortality rate; the systemic inflammatory response plays a vital role in disease progression. We aimed to determine if a miRNA-mRNA co-regulatory network exists in the peripheral blood mononuclear cells (PBMCs) of HBV-ACLF patients, which might be important for prognosis. Methods In patients with HBV-ACLF meeting COSSH-ACLF criteria, age, liver cirrhosis and INR were independent risk factors for 28-day and 90-day poor prognosis. COSSH-ACLFs was a superior prognostic model. mir-6840-3p-JADE2 may promote the progression of ACLF and lead to poor prognosis. Meanwhile, mir-6840-3p and mir-6861-3p can be used as markers of short-term poor prognosis. Finally, ALSS treatment is not only the blood material exchange of patients, but also changes part of the immune state of patients. Among them, cytokine cytokine receptor interaction may play an important role in determining the therapeutic effect. Methods Transcriptome-wide microRNA (miRNA) and mRNA microarrays were used to define the miRNA and mRNA expression profiles of the PBMCs of HBV-ACLF patients in a discovery cohort. The targets of the miRNAs were predicted. We built a miRNA-mRNA regulatory network through bioinformatics analysis, and used quantitative real-time polymerase chain reaction (qRT-PCR) to assess the importance of candidate miRNAs and mRNAs. We also assessed the direct and transcriptional regulatory effects of miRNAs on target mRNAs using a dual-luciferase reporter assay. Results The miRNA/mRNA PBMC expression profiles of the discovery cohort, of whom eight survived and eight died, revealed a prognostic interactive network involving 38 miRNAs and 313 mRNAs; this was constructed by identifying the target genes of the miRNAs. We validated the expression data in another cohort, of whom 43 survived and 35 died; miR-6840-3p, miR-6861-3p, JADE2, and NR3C2 were of particular interest. The levels of miR-6840-3p and miR-6861-3p were significantly increased in the PBMCs of the patients who died, and thus predicted prognosis (areas under the curve values = 0.665 and 0.700, respectively). The dual-luciferase reporter assay indicated that miR-6840-3p directly targeted JADE2. Conclusion We identified a prognostic miRNA-mRNA co-regulatory network in the PBMCs of HBV-ACLF patients. miR-6840-3p-JADE2 is a potential miRNA-mRNA pair contributing to a poor prognosis.

Circulating Human Cytomegalovirus-Encoded Hcmv-Mir-Us4-1 As An Indicator For Predicting The Efficacy Of Ifn Alpha Treatment In Chronic Hepatitis B Patients

Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients

Diagnostic Accuracy of Circulating Micrornas for Hepatitis C Virus-Associated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis

Plasma Microrna Profile As a Predictor of Early Virological Response to Interferon Treatment in Chronic Hepatitis B Patients

Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy

Characterization of Microrna Expression Profiles Associated with Hepatitis B Virus Replication and Clearance in Vivo and in Vitro

MicroRNA Profile in HBV-induced Infection and Hepatocellular Carcinoma.

Identifying potential biomarkers in hepatitis B virus infection and its response to the antiviral therapy by integrated bioinformatic analysis

Cytokine profiles and virological markers highlight distinctive immune statuses, and effectivenesses and limitations of NAs across different courses of chronic HBV infection

Plasma metabolome analysis for predicting antiviral treatment efficacy in chronic hepatitis B: diagnostic biomarkers and therapeutic insights

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

Corrigendum: Identification of a Potential Mirna-Mrna Regulatory Network Associated with the Prognosis of HBV-ACLF.

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Characterisation of Peripheral Blood Mononuclear Cell Microrna in Hepatitis B-related Acute-on-chronic Liver Failure

A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles